🇺🇸 Sphenopalatine Ganglion Block in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Acne — 1 report (10%)
2. Condition Aggravated — 1 report (10%)
3. Coordination Abnormal — 1 report (10%)
4. Cough — 1 report (10%)
5. Dandruff — 1 report (10%)
6. Dry Eye — 1 report (10%)
7. Dry Skin — 1 report (10%)
8. Dysarthria — 1 report (10%)
9. Enuresis — 1 report (10%)
10. Fatigue — 1 report (10%)

Source database →

Frequently asked questions

Is Sphenopalatine Ganglion Block approved in United States?

Sphenopalatine Ganglion Block does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Sphenopalatine Ganglion Block in United States?

University Hospital, Clermont-Ferrand is the originator. The local marketing authorisation holder may differ — check the official source linked above.